Skip to main content
Premium Trial:

Request an Annual Quote

Progenity: Brian Kotzin

Progenity has appointed Brian Kotzin to its board of directors. Kotzin is currently on the board of directors for Rigel, and serves as a principal fellow and senior vice president for Nektar Therapeutics. His previous roles include vice president of global clinical development and head of the inflammation therapeutic area, and vice president and head of medical sciences at Amgen. Prior to entering the life sciences industry, he held several professorships at the University of Colorado Health Sciences Center, where his research focused on immunopathogenesis of disease.

The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.